Last edition
News about
IASO Biotechnology Partners with Instituto Butantan to Localise CAR-T Therapy in Brazil
IASO Bio licenses CAR-T technology to Instituto Butantan for local development in Brazil, aiming to reduce treatment costs and expand public access to advanced therapies for haematological cancer patients.
Haisco Signs Exclusive Deal with AbbVie to Develop Novel Pain Therapies
Haisco partners with AbbVie to develop novel pain therapies, with multiple compounds in preclinical to Phase 1 stages targeting pain-related conditions.
Piramal Pharma Completes US FDA Inspection at Lexington Facility
Piramal Pharma receives US FDA EIR with VAI status for its Lexington facility, marking successful closure of inspection and regulatory compliance.
MHRA Approves Olezarsen (Tryngolza) for Familial Chylomicronemia Syndrome
MHRA approves olezarsen (tryngolza) for adults with Familial Chylomicronemia Syndrome with subcutaneous injection administration.
Trinity Launches InsightsEDGE Digital Twins
Trinity launches InsightsEDGE Digital Twins, using generative AI to turn decades of expertise into real-time, data-driven insights that help life sciences teams anticipate market shifts and optimise commercial decisions.
Daiichi Sankyo Partners with Imagene AI for Biomarker Discovery
Through collaboration, Imagene AI and Daiichi Sankyo will apply multimodal AI to improve biomarker discovery with the goals of advancing precision oncology and enhancing clinical trial success rates.
Sparian Biosciences Begins Phase I Trial of Oral Pain Drug SBS-147 Targeting Opioid Alternatives
Sparian Biosciences advances SBS-147 into Phase I trials, aiming to develop a safer, non-opioid oral treatment for acute and chronic pain.
Ofichem Group Unifies Global Brands Under Single Identity to Streamline Pharma Partnerships
Ofichem consolidates its global brands under one identity to deliver integrated pharmaceutical development and supply solutions.
TAE Life Sciences’ latest research demonstrates the potential of next-generation BNCT to combine targeted radiation with immune activation for improved cancer treatment outcomes.
Avacta Group doses first patient in AVA6103 trial, advances targeted cancer therapy platform
Phase I FOCUS-01 study to evaluate novel peptide-drug conjugate across four solid tumours following Euro 10 million fundraise and collaboration with Tempus AI.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy